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This document is intended to provide general information about the EU accession
process and EU drug policy for NGOs in Central and Eastern Europe (CEE) and the
former Soviet Union (FSU) working the field of harm reduction.  It is intended that after
reading this document and referencing some of the sources cited, such NGOs will be
more able to negotiate effectively with their governments and on an equal footing.  That
is, they will be able to understand the vocabulary of the accession process and the EU
and apply the principles of EU drug policy to their own countries in order to craft
arguments for satisfactory drug policies in their own countries.  Familiarity with these
concepts and arguments may also be useful when applying to foundations, international
organizations and governments for funding.  The first part of this document provides an
overview of the EU accession process, highlighting areas of relevance to drug policy.
The second part of this document outlines current EU drug policy, highlighting areas of
relevance to countries of CEE and FSU.
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 THE EU ACCESSION PROCESS
This guide is intended to provide
general background information about
the EU accession process to NGOs
involved in harm reduction in candidate
countries; it is not intended to be a
comprehensive explanation.
Currently there are fifteen member
countries in the European Union and
thirteen candidate countries who are in
the middle of the accession process.
In
general, the
EU strives
to balance
national
sovereignty
with
effective,
cohesive
internationa
l policies.
This is
achieved
through the
promulgatio
n of general
guidelines
with
allowances
for
variations among individual states.  The
accession process is no different.  The
general process described below is the
same for all the candidate countries,
however each candidate country has
different policy areas to address
depending upon the strengths of its
infrastructure.  The goal of the accession
process is to bring the governments and
economies of the candidate countries in
line with the acquis communitaire
(acquis)  of the EU.  The acquis is not
precisely defined nor is it explicated in a
document.  It is the unwritten law of the
EU as applied to laws, regulations,
economies and governments of the EU
itself and its member states.  In the
accession process, candidate countries
attempt to harmonize their laws,
regulations, and economic and
government structures with those of the
member states.  The goal is not to draft
laws identical to the member states, but
to draft and implement laws that are
appropriate to the candidate state, and
are in harmony with the acquis of the
member states.  The acquis consists of
29 “chapters” (or topics) ranging from
company law to agriculture; science and
research to culture and audio-visual
policy among others.  Drug policy is
addressed in Chapter 24, “Cooperation
in the Field
of Justice
and Home
Affairs.”
There
are four
documents
published
by the EU
and
candidate
countries
that may be
useful to
NGOs in
order to
determine
the current
policies and
goals of
their governments, and evaluate the
progress in implementation.  They are
all publicly available.
Europe Agreements are developed
through negotiations between
government officials of the candidate
countries and ministers of the EU.  They
are signed by the member states and
the candidate country.  Each candidate
country has its own agreement which
provides the framework to prepare the
country for entry to the EU.  The Europe
Agreement provides for gradual opening
of markets as well as social and legal
aspects of integration.  These
Agreements tend to be around 75 pages
long.  All of the Europe Agreements are
available on the Internet.  Drugs have
their own article under Title VI,
“Economic Cooperation.”  This is usually
a general statement about how member
states will work with candidates to
RELEVANT INTERNET SITES
EU homepage:
http://europa.eu.int/index_en.htm
Overview of the enlargement process:
http://europa.eu.int/comm/enlargement/overview.htm
Europe Agreements:
http://europa.eu.int/comm/enlargement/pas/europe_agr.htm
Accession Partnerships:
http://europa.eu.int/comm/enlargement/report_10_99/acc_partn.htm
Regular Reports for the year 2000:
http://europa.eu.int/comm/enlargement/report_11_00/index.htm
EU Drug Strategy:
http://www.emcdda.org/policy_law/eu/eu_actionplan.shtml
EMCDDA:
http://www.emcdda.org/
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control supply and reduce demand.
Drugs are mentioned again in Protocol
61, Mutual Assistance in Customs
Matters, stating that information
gathered by customs authorities
concerning drugs should be reported to
authorities combating illicit drug use.
Accession Partnerships concisely
outline the priorities for each candidate
                                          
1 A protocol is an amendment to a treaty.
2 “Communication from the Commission to the
Council and The European Parliament on the
Implementation of the EU Action Plan on Drugs
(2000-2004) COM(2001) 301 final.
3 “Drug Co-ordinators Meet Under Spanish
Presidency,” Drugnet Europe, No. 36, July-August
2002 p. 1.
4 See “EU-Action Plan on Drugs 2000-2004”
9283/00 CORDROGUE 32, 7 June 2002, page 3
Available at:
http://www.emcdda.org/multimedia/actionplan/cor
drogue32en.pdf.
5 EMCDDA, “2001 Annual Report on the State of
the Drugs Problem in the European Union,” page
48, available at: http://annualreport.emcdda.org/
see also Communication from the Commission to
the Council and the European Parliament on the
Implementation of the EU Action Plan on Drugs
(2000-2004), COM(20001) 301 Final, page 7.
6 id.
7 id.
country and set targets for each
candidate country to achieve.  Accession
Partnerships are updated periodically
and cover all aspects of the acquis.
Proposals made by the Commission to
the applicant states are decided upon by
the Council.  The Council determines EU
assistance to candidate states based
upon progress in implementing the
Accession Partnerships.  Specific
information on drug policy can be found
under the heading “Justice and Home
Affairs.”  Health policy, of relevance to
those active in harm reduction
programs, is often referred to under the
heading “Social Policy and Employment.”
National Programs for the Adoption
of the Acquis (NPAA) are developed by
each candidate country.  They are
detailed plans for the implementation of
the Accession Partnership. They usually
include information on funding and
timetables.  Though public record, they
are not available on a centralized
Internet site.  Each country publishes
them independently, often available on
the government’s webpage. Information
on drug policy can usually be found in
THE IMPORTANCE OF THE DRUG POLICY OF CANDIDATE COUNTRIES TO THE EU
The EU has included the EU candidate countries in its drug strategy.  The 2001 Report
on the State of Drug Use in the EU devotes a chapter entirely to CEE and the EU
Commission has stated it, “considers stepping up the fight against drugs in the applicant
countries as a priority.”2.  Furthermore, National Drug Coordinators of member states and
candidate countries met May 21, 2002, and “stressed the need for political support in the
candidate countries to keep drugs on the agenda.”3
Ensuring that candidate states address illicit drugs is based in part upon concern that
illegal drugs are entering the EU through the countries of CEE/FSU.4  The 2001 Annual
Report on the state of the drugs problem in the European Union reports drug seizures
which indicate that some candidate countries including: Turkey, Romania, Hungary, the
Czech Republic and the Balkans serve as transit routes for drugs such as cocaine, heroin
and marijuana which are destined form EU Member states.5  Furthermore, illegal
laboratories producing synthetic drugs have been dismantled throughout the region,
particularly in the Baltic states, Poland, the Czech Republic and Bulgaria. 6  More labs are
suspected to exist.7  By addressing the demand for these drugs in Eastern Europe, EU
countries may be able to decrease the flow of these drugs to Western Europe.
Further examples of the emphasis the EU is putting on drug policy in candidate
countries can be found in the EMCDDA and the Phare programme.  (For more information
about these, see the text boxes.)  Candidate states are invited to participate in the
EMCDDA before the accession process is complete.  For nearly ten years the EU provided
financial and technical support to counter the drugs problem to countries of CEE/FSU in
the form of the Phare Multi-Beneficiary Drugs Programme.
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the “Justice and Home Affairs”
discussion.
Regular Reports are yearly reports
published by the EU each September
that examine how close each candidate
country is to complying with the NPAA.
It examines each chapter of the acquis
in turn.  In evaluating the progress of
the candidate countries, they emphasize
that passing legislation alone is not
adequate for compliance: the legislation
should be enforced.  Reports evaluating
the progress of candidate countries in
2001, will be available in September
2002.  In Chapter 24, “Justice and Home
Affairs,” information on drug policy can
be found.
THE DRUG POLICY OF THE EU
GENERAL PRINCIPLES
In December 1999 the EU developed
the European Union Drug Strategy
(2000-2004).  The strategy includes six
Main Targets and eleven General Aims.
These are listed in the later in this
document, and the full Drug Strategy is
available on the Internet.  The Action
Plan on Drugs (2000-2004) implements
the Drug Strategy.   Following is a
summary of aspects of current EU drug
policy of particular relevance to CEE and
FSU countries in the accession process.
This summary is  based upon the Drug
Strategy as well as other EU documents
including publications of the European
Monitoring Center for Drugs and Drug
Addiction (EMCDDA).
First, it should be noted that the EU
considers addressing drug problems a
high priority for both internal and
external action.  This is the first General
Aim of the Drug Strategy.  The
importance to the EU of addressing the
drug problem is also highlighted in the
treaties establishing the European
Economic Community and the European
Union which mention drugs as an issue
that requires international cooperation to
be dealt with effectively.  Drug abuse is
mentioned in the field of public health8
                                          
8 Treaty Establishing the European Community,
Article 152.
EMCDDA
In 1993 the EU established the
European Monitoring Center for Drugs
and Drug Addiction.  EMCDDA does not
develop policy, rather it gathers and
analyzes data about drug use and
treatment in Europe and related issues
such as infectious diseases.  The
EMCDDA focuses on 4 main priorities:
1) monitoring the situation of drug
use, 2) monitoring the responses to
drug use, 3) implementing the EU
action plan on new synthetic drugs,
and 4) monitoring national and
Community strategies and their
impact.
EMCDDA also publishes Drugnet, a bi-
monthly newsletter and Drugs in
Focus, a bimonthly briefing on specific
policy issues. Both are available on the
Internet.  EMCDDA also publishes
periodical reports describing and
evaluating the effectiveness of demand
reduction strategies employed by EU
countries.  Current initiatives include
examining pill testing and safe drug
consumption rooms.
Justice and Home Affairs
The structure of the EU is based upon
the three pillars of the European
Economic Community, Common
Foreign and Security Policy, and
Justice and Home Affairs. In response
to opening international borders to
the free movement of persons, the
EU has established mechanisms for
ensuring peace and freedom within
its borders.  These mechanisms and
policies form the third “pillar”  of the
EU: Justice and Home Affairs.
Policies concerning organized crime,
including drug trafficking, are
coordinated under this pillar.
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and drug trafficking is mentioned in the
context of public safety.9
Second, the EU sees that supply
control and demand reduction are
mutually reinforcing and thus drug
related problems should be addressed
with an interdisciplinary approach.  This
perspective is based upon the 1998 UN
General Assembly Resolution,
Declaration on the Guiding Principles of
Drug Demand Reduction which states,
“The most effective approach to the drug
problem consists of a comprehensive,
balanced and coordinated approach, by
which supply control and demand
reduction reinforce each other, together
with appropriate application of the
principle of shared responsibility.”10  This
approach is reflected in Justice and
Home Affairs (JHA) policy which
recognizes that law enforcement cannot
effectively address the problem alone
and that education, treatment and
reintegration into the community are
fundamental.  Thus, though drug policy
is often addressed under the heading
JHA in the
accession documents discussed above,
demand reduction is still considered a
key component.  The Public Health
strategy for dealing with drug related
problems also calls for a “multi-
disciplinary” approach.11    Finally, The
                                          
9 Treaty of Amsterdam, Article 29.
10 “Declaration on the Guiding Principles of
Demand Reduction,” A/RES/S-20/3. I.4
11 Decision No 102/97/EC Of the European
Parliament and of the Council of 16 December
1996 adopting a programme of Community action
Action Plan approves of Phare’s
encouragement of a balanced approach
by supporting a multi-sectoral approach
to demand reduction.
EU’S CONCERNS
There are four reoccurring concerns
that appear in the EU’s literature on
drug policy and are of particular
relevance to CEE and FSU countries
preparing to accede to the EU: the
public health aspects of drug use, the
involvement of civil society in
addressing drug problems, the
collection of accurate data about drug
use and its effects, and ensuring that
the needs of vulnerable groups are
addressed.
1. The E.U. is concerned with the
public health aspects of drug use
E.U. drug policy recognizes that
drug abuse poses public health
problems.  This is evident even in the
treaty establishing the European
Community (a precursor to the European
Union) which recognizes that
coordinated action between nations is
necessary to address illnesses, diseases
and scourges.12  Drug related health
damage is specifically mentioned,
highlighting the high priority being
placed upon it. Moreover, the EU has
established a “Community action
programme for the prevention of drug
dependence within the framework for
action in the field of public health.”  In
addition to striving to prevent drug
addiction, the Programme, seeks to
                                                            
on the prevention of drug dependence within the
framework for action in the field of public health
(1996-2000), Para. 11.
12 Treaty Establishing the European Community,
Article 152
Phare
Phare provides funding and
technical assistance to candidate
countries to assist them in fulfilling
their Accession Partnerships.  The
programmes may be designed for
one particular country or many.   A
key component of many programs
is pairing member states with
candidate countries otherwise
known as “twinning.” The Phare
Drugs Program expired in
December 2001.
AREAS OF CONCERN FOR
EU DRUG POLICY
•  Public Health
•  Civil Society
•  Data Collection
•  Vulnerable Groups
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mitigate the risks incurred by injecting
drug users such as: HIV, Hepatitis B,
Hepatitis C, Tuberculosis, abscesses,
endocarditis, and overdoses.   Other EU
documents indicate that the primary risk
referred to is the transmission of
infectious diseases such as Hepatitis B
and C and HIV.     For example 50-80%
of injecting drug users have Hepatitis C,
“underlining that containing the spread
of infectious diseases among (and from)
drug injectors remains a priority.”13  The
concern of the EU with the public health
consequences of drug abuse is further
supported by the focus on HIV/AIDS in
its press release on the Day Against
Drugs.14  Finally, the second target of
the EU Drug Strategy is to “reduce drug
related health damage (particularly HIV)
and drug related deaths.”
Relevance to Candidate Countries
Public health consequences of
injection drug use are of vital concern to
countries in FSU and CEE where HIV is
spreading faster than anywhere else in
the world.15  Injecting drug users make
up 88% of all HIV/AIDS cases in the
FSU.16  Some countries of CEE have low
rates of HIV infection, however the
increase in the use of injection drugs
indicates that there may be a rise.  This
makes the need for harm reduction
programs all the more urgent.  For
example, needle exchange programs are
most effective when needles are
provided to a large portion of the
population.  Because in some CEE
countries there are relatively few
addicts, it is logistically easier and less
expensive for harm reduction programs
to provide needles to a larger portion of
addicts.  EU reports have suggested that
                                          
13 Richard Hartnoll, “Feature: Current Trends in
Drug Use and Challenges for Public-Health Policy,”
Drugnet Europe, No. 35, May-June 2002, Page 4.
14 “HIV/AIDS ‘Still a Big Problem’ Among EU Drug
Users, Says Drug Agency,’ 26 June 2002, available
at: http://www.emcdda.org/data/docs/33en.pdf
15 UNAIDS, “Report on the Global HIV/AIDS
Epidemic 2002” page 32, available at:
http://www.unaids.org/barcelona/presskit/barcelo
na%20report/chapter2.pdf
16 Central and Eastern Europe Harm Reduction
Network, “Injecting Drug Users, HIV/AIDS
Treatment and Primary Care in Central and Eastern
Europe and the Former Soviet Union” page 3
had more needle exchange programs
been available, more HIV/AIDS cases
could have been prevented.17  Thus in
Central European countries where there
are few cases of HIV among intravenous
drug users, an increase in HIV infections
can be prevented through needle
exchanges.  On the other hand,  the
drastic increases in HIV infection be
stemmed through needle exchanges in
the countries of the FSU.
2. Civil society should be
involved in addressing drug
problems
The EU recognizes that the
involvement of civil society is necessary
in addressing drug problems.  This is
implicit in the calls for a multi-
disciplinary approach to drug policy and
in the goal of data collection.  NGOs,
particularly low threshold services, are
essential in collecting accurate data from
drug users, who often do not trust
government officials.  The involvement
of civil society is explicitly called for in
the sixth General Aim of the Drug
Strategy.
Relevance to candidate countries
Strengthening civil society in CEE is
also a goal of the EU accession process.
The “European Parliament, the Economic
and Social Committee and the
Committee of Regions have called for
the closer involvement of civil society in
the process.”18  Also, one of objectives
of Phare’s Drugs Programme was to
enhance the basis of civil society by
including NGOs in prevention activities,19
                                          
17 “Overall the EMCDDA is concerned that if control
measures such as prevention including needle
exchange and condom availability had been
sufficient, the problem of HIV/AIDS among IDUs
should have been slowly diminishing in the most-
affected areas.” HIV/AIDS ‘Still a Big Problem’
Among EU Drug Users, Says Drug Agency, News
Release No. 5/2002 – 26 June 2002.
18 “Making a Success of Enlargement: Strategy
Paper and Report of the European Commission on
the Progress Towards Accession by each of the
candidate Countries” page 14, available at:
http://europa.eu.int/comm/enlargement/report200
1/index.htm#Strategy Paper 2001
19 Phare Multi-Beneficiary Programme, Drugs
Programme, Programme Description, Specific
Objective 6, available at:
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and, partnership between governments
and NGOs is important for CEE strategy
plans.20
3. Addressing drug problems
requires the collection of
accurate data about drug abuse
Accurate data collection about drug
use patterns and the health of drug
users is necessary for evaluating drug
policies, assisting law enforcement
efforts and addressing public health
concerns.  General Aim of the Action
Plan is “to ensure collection, analysis
and dissemination of objective, reliable
and comparable data on the drugs
phenomenon in the EU with the support
of EMCDDA and Europol.”  Thus, the EU
established the EMCDDA and the Reitox
network of national focal points to
coordinate data collection from individual
nations.
Relevance to candidate countries
Since 1993, candidate countries have
received EU assistance in developing
data collection strategies in harmony
with the member states.  Candidate
countries are permitted to become
members of the EMCDDA before the
accession process is completed.
4. EU Drug Policy targets
vulnerable groups.
The EU is concerned that the drug
abuse of vulnerable groups be
addressed.  Vulnerable groups include
youth,21 parents22, minorities,23 and
prisoners24.
Relevance to Candidate Countries
                                                            
http://europa.eu.int/comm/enlargement/pas/phar
e/programmes/multi-bene/drugs.pdf
20 EMCDDA, “2001 Annual Report on the State of
the Drugs Problem in the European Union,” page
50, available at: http://annualreport.emcdda.org/.
21 See General Aim 8 of EU Drug Strategy
22 Communication from the Commission to the
Council and the European Parliament on a
European Action Plan to Combat Drugs (2000-
2004) COM (1999) 239 final, p. 37 available at:
http://www.emcdda.org/multimedia/actionplan/act
ion_en.pdf.
23 id.
24 id.
Youth, parents and prisoners are just
as vulnerable to drug abuse and its
negative effects in candidate countries
as they are in the EU.  Furthermore
there are some minority groups in
candidate countries that are particularly
vulnerable.  For example, Roma are at
particular risk of drug use and HIV
infection due to their poverty and lack of
access to health services.25
                                          
25 “Drugs, AIDS, and Harm Reduction: How to Slow
the HIV Epidemic in Eastern Europe and the
Former Soviet Union,” International Harm
Reduction Development, Open Society Institute,
p. 15
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ELEVEN GENERAL AIMS OF EU ACTION PLAN
1. To ensure that the issue of drugs is kept a major priority for EU internal and
external action.
2. To ensure that actions against drugs are evaluated
3. To continue the EU global, multidisciplinary, integrated and balanced strategy, in
which supply and demand reduction are seen as mutually reinforcing elements, as
underlined by the United Nations General Assembly Special Session on Drugs
(UNGASS).
4. To give greater priority to drug prevention and demand reduction, particularly new
recruitment to drug use, as well as the reduction of the adverse consequences of
drug use.
5. To reinforce the fight against organized crime, illicit drug trafficking and related
organized crime as well as other drug-related crime, and to step up police, customs
and judicial co-operation between Member States.
6. To encourage multi-agency cooperation and the involvement of civil society.
7. To fully utilize the new possibilities offered by the Treaty of Amsterdam, particularly
the articles on health protection and drug control…[police stuff]
8. To ensure collection, analysis and dissemination of objective, reliable and
comparable data on the drugs phenomenon in the EU with the support of EMCDDA
and Europol
9. To progressively integrate candidate countries and to intensify international
cooperation with other countries and international organizations.
10. To promote international cooperation, integration of drug control into EU
development co-operation and to support the efforts of the United Nations and of
UNDCP in particular to develop international co-operation, based on the principles
adopted at the UNGASS in June 1988.
11. To emphasise that the successful implementation of the strategy and actions
mentioned in this Strategy will necessitate appropriate resources.
SIX TARGETS OF EU ACTION PLAN
1. Reduce prevalence of drug use
2. Reduce drug related health damage (particularly HIV) and drug-
related deaths
3. Increase number of successfully treated addicts
4. Reduce availability of illicit drugs
5. Reduce drug related crime
6. Reduce money laundering and illicit trafficking of precursors.
